ECS05
DRUG DELIVERY CONTACT LENS TECHNOLOGY TO TREAT EYE DISEASE
C. Adams1,*
1Glint Pharmaceuticals, Cambridge, United States
Glint has developed a novel, patented approach for extended drug delivery by the incorporation of vitamin E (α tocopherol) in commercial silicon hydrogel contact lenses. The use of commercial contact lenses that are already approved by the FDA, reduces barriers to translation. The drug eluding Glint contact lens maintain transparency, wettability, UV-blocking capability, as well as oxygen and ion permeability. The Glint approach has a competitive advantage over other ocular drug delivery technologies. The technology uses commercial lenses, is easily scalable and can deliver multiple drugs separately or in combination.
The Glint lens provides a new, non-surgical method to treat eye disease, increasing patient compliance while delivering appropriate drug to the eye. Improving drug delivery efficiency to the ocular tissue may help reduce the incidence of serious ocular complications and blindness. Sustained release will eliminate the need for multiple drops each day.
Corneal injury from trauma, infection, or surgery affects over 8,000,000 people per year in the US and Europe. Blindness occurs in a significant number of cases. The single or multi drug eluting contact lens will not only offer convenience and cost savings for eye care providers but will eliminate the drop burden for patients and their care givers while enhancing compliance.
*Please note the company website has been changed since submission.